S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
Important info on NVDA trade (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
Important info on NVDA trade (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
Important info on NVDA trade (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
Important info on NVDA trade (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions

Transphorm Stock Price, News & Analysis (OTCMKTS:TGAN)

$2.94
+0.09 (+3.16%)
(As of 11/27/2023 ET)
Compare
Today's Range
$2.82
$2.97
50-Day Range
$1.98
$2.95
52-Week Range
$1.94
$6.69
Volume
117,877 shs
Average Volume
49,132 shs
Market Capitalization
$182.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.75

Transphorm MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
95.6% Upside
$5.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.51) to ($0.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.58 out of 5 stars


TGAN stock logo

About Transphorm Stock (OTCMKTS:TGAN)

Transphorm, Inc., a semiconductor company, develops, manufactures, and sells gallium nitride (GaN) semiconductor components for high voltage power conversion applications in Mainland China, Hong Kong, Taiwan, the United States, Japan, South Korea, India, and Europe. The company's products include GaN field effect transistors in various packages. Its GaN devices allows customers to design power systems creating functional value in various end products, including smartphone power adapters/fast-chargers, power supplies for datacenter servers/communication, industrial power converters, chargers/converters/inverters for electric vehicles, and other applications. The company offers its products through regional distributors and sales representatives. Transphorm, Inc. was founded in 2007 and is headquartered in Goleta, California.

TGAN Stock Price History

TGAN Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Transphorm Stock: Maybe Not Fast Enough
Transphorm (TGAN) Receives a Buy from Benchmark Co.
Transphorm Announces Results of Rights Offering
TGAN - Transphorm, Inc.
Transphorm: Q4 Earnings Insights
See More Headlines
Receive TGAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Transphorm and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
11/28/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Semiconductor Equipment & Materials
Sub-Industry
N/A
Current Symbol
OTCMKTS:TGAN
Fax
N/A
Employees
131
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.75
High Stock Price Target
$8.00
Low Stock Price Target
$3.50
Potential Upside/Downside
+95.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-30,600,000.00
Net Margins
-189.65%
Pretax Margin
-189.65%

Debt

Sales & Book Value

Annual Sales
$18.58 million
Book Value
$0.33 per share

Miscellaneous

Free Float
60,188,000
Market Cap
$182.16 million
Optionable
Not Optionable
Beta
0.42
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Primit A. Parikh Ph.D. (Age 51)
    Co-Founder, President, CEO & Director
    Comp: $390.66k
  • Mr. Cameron McAulay (Age 47)
    Chief Financial Officer
    Comp: $350.66k
  • Dr. Umesh K. Mishra Ph.D. (Age 65)
    Chairman & CTO
    Comp: $180k
  • Mr. Philip Zuk
    Senior Vice President of Business Development & Marketing
  • Mr. Tushar Dhayagude
    Vice President of Worldwide Sales
  • Mr. Randy Berg
    Human Resources Leader
  • Mr. Sal Barlett
    Senior Vice President of Operations














TGAN Stock Analysis - Frequently Asked Questions

Should I buy or sell Transphorm stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Transphorm in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TGAN shares.
View TGAN analyst ratings
or view top-rated stocks.

What is Transphorm's stock price target for 2024?

2 analysts have issued 12-month target prices for Transphorm's shares. Their TGAN share price targets range from $3.50 to $8.00. On average, they predict the company's stock price to reach $5.75 in the next year. This suggests a possible upside of 95.6% from the stock's current price.
View analysts price targets for TGAN
or view top-rated stocks among Wall Street analysts.

How have TGAN shares performed in 2023?

Transphorm's stock was trading at $5.44 at the start of the year. Since then, TGAN shares have decreased by 46.0% and is now trading at $2.94.
View the best growth stocks for 2023 here
.

How were Transphorm's earnings last quarter?

Transphorm, Inc. (OTCMKTS:TGAN) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. The business had revenue of $5.01 million for the quarter, compared to the consensus estimate of $5.40 million. Transphorm had a negative trailing twelve-month return on equity of 114.30% and a negative net margin of 189.65%.

How do I buy shares of Transphorm?

Shares of TGAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:TGAN) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -